Conmed Q2 sales, adjusted profit beat on organic platform growth
CNMD•Outlook and growth drivers
The company updated its 2026 guidance after organic growth in core surgery lines.
CONMED sees 2026 net sales between $1.358 bln and $1.373 bln and expects 2026 adjusted diluted EPS of $4.48 to $4.60.
The company said organic sales growth was driven by exits from GI product lines as part of its portfolio optimization strategy. Year-over-year organic growth in Orthopedic Surgery and General Surgery lines was attributed to focus on AirSeal, Buffalo Filter, and BioBrace platforms.
Q2 adjusted EPS included a $0.21 per share benefit from IEEPA tariff refunds.
Analyst coverage and valuation
The current average analyst rating on the shares is hold, with no strong buy or buy ratings, 6 hold ratings and 1 sell or strong sell rating.
The average consensus recommendation for the medical equipment, supplies & distribution peer group is buy.
Wall Street's median 12-month price target for Conmed Corp is $39.00, about 11.9% below its July 28 closing price of .
